Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

10.1186/s12885-018-5110-2

Saved in:

Bibliographic Details
Main Authors:	Tan, Wan-Ling, Ng, Quan Sing, Lim, Cindy, Tan, Eng Huat, Toh, Chee Keong, Ang, Mei-Kim, Kanesvaran, Ravindran, Jain, Amit, Tan, Daniel SW, Lim, Darren Wan-Teck
Other Authors:	DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
Format:	Article
Language:	English
Published:	BMC 2022
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology EGFR mutation NSCLC Metastatic Afatinib Brain metastases Dose CELL LUNG-CANCER RECEPTOR GENE-MUTATIONS INTERNATIONAL-ASSOCIATION EFFICACY ADENOCARCINOMA GEFITINIB ERLOTINIB SAFETY COMMON
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/218617
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

id	sg-nus-scholar.10635-218617
record_format	dspace
spelling	sg-nus-scholar.10635-2186172024-11-15T00:40:05Z Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases Tan, Wan-Ling Ng, Quan Sing Lim, Cindy Tan, Eng Huat Toh, Chee Keong Ang, Mei-Kim Kanesvaran, Ravindran Jain, Amit Tan, Daniel SW Lim, Darren Wan-Teck DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) DUKE-NUS MEDICAL SCHOOL Assoc Prof Wan-Teck Darren Lim Science & Technology Life Sciences & Biomedicine Oncology EGFR mutation NSCLC Metastatic Afatinib Brain metastases Dose CELL LUNG-CANCER RECEPTOR GENE-MUTATIONS INTERNATIONAL-ASSOCIATION EFFICACY ADENOCARCINOMA GEFITINIB ERLOTINIB SAFETY COMMON 10.1186/s12885-018-5110-2 BMC CANCER 18 1 2022-04-07T08:39:27Z 2022-04-07T08:39:27Z 2018-12-03 2022-04-07T02:40:13Z Article Tan, Wan-Ling, Ng, Quan Sing, Lim, Cindy, Tan, Eng Huat, Toh, Chee Keong, Ang, Mei-Kim, Kanesvaran, Ravindran, Jain, Amit, Tan, Daniel SW, Lim, Darren Wan-Teck (2018-12-03). Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. BMC CANCER 18 (1). ScholarBank@NUS Repository. https://doi.org/10.1186/s12885-018-5110-2 14712407 https://scholarbank.nus.edu.sg/handle/10635/218617 en BMC Elements
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
language	English
topic	Science & Technology Life Sciences & Biomedicine Oncology EGFR mutation NSCLC Metastatic Afatinib Brain metastases Dose CELL LUNG-CANCER RECEPTOR GENE-MUTATIONS INTERNATIONAL-ASSOCIATION EFFICACY ADENOCARCINOMA GEFITINIB ERLOTINIB SAFETY COMMON
spellingShingle	Science & Technology Life Sciences & Biomedicine Oncology EGFR mutation NSCLC Metastatic Afatinib Brain metastases Dose CELL LUNG-CANCER RECEPTOR GENE-MUTATIONS INTERNATIONAL-ASSOCIATION EFFICACY ADENOCARCINOMA GEFITINIB ERLOTINIB SAFETY COMMON Tan, Wan-Ling Ng, Quan Sing Lim, Cindy Tan, Eng Huat Toh, Chee Keong Ang, Mei-Kim Kanesvaran, Ravindran Jain, Amit Tan, Daniel SW Lim, Darren Wan-Teck Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
description	10.1186/s12885-018-5110-2
author2	DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
author_facet	DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) Tan, Wan-Ling Ng, Quan Sing Lim, Cindy Tan, Eng Huat Toh, Chee Keong Ang, Mei-Kim Kanesvaran, Ravindran Jain, Amit Tan, Daniel SW Lim, Darren Wan-Teck
format	Article
author	Tan, Wan-Ling Ng, Quan Sing Lim, Cindy Tan, Eng Huat Toh, Chee Keong Ang, Mei-Kim Kanesvaran, Ravindran Jain, Amit Tan, Daniel SW Lim, Darren Wan-Teck
author_sort	Tan, Wan-Ling
title	Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
title_short	Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
title_full	Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
title_fullStr	Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
title_full_unstemmed	Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
title_sort	influence of afatinib dose on outcomes of advanced egfr-mutant nsclc patients with brain metastases
publisher	BMC
publishDate	2022
url	https://scholarbank.nus.edu.sg/handle/10635/218617
_version_	1821194808557830144

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Similar Items